Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EVH
EVH logo

EVH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.325
Open
2.200
VWAP
2.24
Vol
2.50M
Mkt Cap
254.54M
Low
2.130
Amount
5.60M
EV/EBITDA(TTM)
8.97
Total Shares
111.64M
EV
1.06B
EV/OCF(TTM)
27.31
P/S(TTM)
0.13
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
Show More

Events Timeline

(ET)
2026-03-19
09:00:00
Evolent Health Appoints Archie Mayani as Chief Product Officer
select
2026-03-02 (ET)
2026-03-02
07:40:00
Oppenheimer Lowers Evolent Health Price Target to $6
select
2026-02-25 (ET)
2026-02-25
16:40:00
Nasdaq Rises 1.26% as Investors Await Nvidia Earnings
select
2026-02-25
12:10:00
Nasdaq Rises 1.09% as Nvidia Earnings Report Draws Attention
select

News

PRnewswire
5.0
03-19PRnewswire
Evolent Health Appoints New Chief Product Officer
  • Leadership Change: Evolent Health has appointed Archie Mayani as Chief Product Officer, bringing over 20 years of leadership experience in health tech and AI, which is expected to accelerate the company's product strategy.
  • Innovative Background: Prior to joining Evolent, Mayani served as CPO at GHX, where she pioneered AI-driven capabilities to enhance the resilience of the global healthcare supply chain, providing valuable experience for Evolent's product innovation.
  • Performance Enhancement: At Change Healthcare, Mayani focused on innovations in clinical decision support and revenue cycle platforms, helping to reduce administrative burdens for providers and payers, which is anticipated to improve Evolent's product efficiency and market competitiveness.
  • Industry Recognition: Mayani has received multiple industry awards, including the Inspiring Leader Award at the 2023 Health 2.0 conference, showcasing her influence and leadership in the healthcare sector, which will enhance Evolent's industry reputation.
Newsfilter
5.0
03-18Newsfilter
Foodsmart Appoints New Board Member to Advance Foodcare in Medicaid
  • New Board Member: Foodsmart has appointed Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, to its Board of Directors, bringing extensive value-based care experience that is expected to drive growth in the Medicaid sector.
  • Integration of Nutrition Care: Ajayi emphasizes the critical role of nutrition support within healthcare systems, as Foodsmart aims to improve health outcomes and reduce overall costs for over 3 million members by integrating nutrition care with medical services.
  • Advancing Health Equity: Ajayi's appointment will enhance Foodsmart's impact on Medicaid and high-need populations, promoting health equity and ensuring that patients with complex medical needs have access to essential nutrition support.
  • Industry Recognition: Ajayi's leadership and innovative models in value-based care have garnered widespread recognition, and her experience will provide valuable strategic guidance for Foodsmart to stand out in a competitive market.
moomoo
4.0
03-02moomoo
EVOLENT HEALTH: OPPENHEIMER LOWERS PRICE TARGET FROM $12 TO $6
  • Stock Price Adjustment: Evolent Health has reduced its target price from $12 to $6.
  • Market Impact: This significant cut in target price may reflect changes in market conditions or company performance.
PRnewswire
1.0
02-26PRnewswire
Evolent Health to Participate in Investor Conferences
  • Executive Participation: Evolent Health's executive management team will participate in upcoming investor conferences, aiming to enhance the company's transparency and trust in the capital markets through direct interaction with investors.
  • Webcast Availability: The events will feature live audio webcasts and replays, allowing investors to access relevant information via Evolent's investor relations website, ensuring timely communication and broad outreach.
  • Company Mission: Evolent specializes in achieving better health outcomes for individuals with complex conditions through solutions that simplify and reduce healthcare costs, thereby enhancing its competitive position in the healthcare industry.
  • Industry Recognition: Evolent is consistently recognized as one of the top places to work in healthcare nationally, demonstrating its success in attracting and retaining talent, which further solidifies its leadership in the healthcare services sector.
seekingalpha
9.5
02-25seekingalpha
Evolent Health Q4 2025 Earnings Call Insights
  • Revenue and EBITDA Performance: Evolent Health reported Q4 2025 revenue of $469 million and adjusted EBITDA of $37.8 million, both exceeding the midpoint of guidance, indicating sustained momentum in organic growth and profitability.
  • Future Growth Expectations: CEO Seth Blackley forecasts approximately 30% revenue growth in 2026, with 65% of revenue expected to come from oncology, up from 36% in 2025, highlighting a strategic shift towards high-growth areas.
  • Customer and Contract Expansion: The company migrated approximately 90% of Performance Suite revenue under a new model, retaining all key customers and signing two major new clients in the past year, enhancing market competitiveness and customer base.
  • Financial Outlook and Challenges: Despite anticipating a $40 million headwind from exchange membership declines, the company plans to achieve $2.5 billion in revenue and $125 million in adjusted EBITDA, demonstrating confidence in future growth.
seekingalpha
4.0
02-25seekingalpha
KeyBanc Downgrades Evolent Health Rating Amid EBITDA Concerns
  • Rating Downgrade: KeyBanc Capital Markets downgraded Evolent Health from overweight to sector weight due to concerns over the company's future EBITDA performance, reflecting a cautious market sentiment regarding its profitability.
  • Earnings Beat: Despite the Q4 financial results released on the same day exceeding market expectations, analyst Matthew Gillmor noted that EBITDA is expected to be heavily weighted in H2 at 70%, indicating seasonal volatility in the company's earnings.
  • Future Outlook: Gillmor also mentioned that the Street EBITDA target for 2027 is expected to be lowered to $187 million, suggesting a decline in market confidence regarding the company's long-term profitability.
  • Strong Demand: Despite the downgrade, Evolent's late-stage pipeline remains robust, and high renewal rates with existing customers reflect strong demand among health plans to control specialty costs, particularly in oncology, supporting the company's shift to the PS 2.0 model.
Wall Street analysts forecast EVH stock price to rise
14 Analyst Rating
Wall Street analysts forecast EVH stock price to rise
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
5.00
Averages
9.33
High
16.00
Current: 0.000
sliders
Low
5.00
Averages
9.33
High
16.00
UBS
Buy -> Buy
downgrade
$10 -> $5
AI Analysis
2026-02-26
Reason
UBS
Price Target
$10 -> $5
AI Analysis
2026-02-26
downgrade
Buy -> Buy
Reason
UBS lowered the firm's price target on Evolent Health to $5 from $10 and keeps a Buy rating on the shares.
Citi
Buy -> Buy
downgrade
$6 -> $4
2026-02-26
Reason
Citi
Price Target
$6 -> $4
2026-02-26
downgrade
Buy -> Buy
Reason
Citi lowered the firm's price target on Evolent Health to $4 from $6 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EVH
Unlock Now

Valuation Metrics

The current forward P/E ratio for Evolent Health Inc (EVH.N) is 16.41, compared to its 5-year average forward P/E of 54.97. For a more detailed relative valuation and DCF analysis to assess Evolent Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
54.97
Current PE
16.41
Overvalued PE
297.14
Undervalued PE
-187.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.54
Current EV/EBITDA
9.44
Overvalued EV/EBITDA
29.30
Undervalued EV/EBITDA
11.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.40
Current PS
0.19
Overvalued PS
2.06
Undervalued PS
0.75

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top loosers which i can buy now today
Intellectia · 23 candidates
Market Cap: >= 50.00MPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: <= $-8.00
Ticker
Name
Market Cap$
top bottom
OMEX logo
OMEX
Odyssey Marine Exploration Inc
68.00M
ACHV logo
ACHV
Achieve Life Sciences Inc
215.60M
AHMA logo
AHMA
Ambitions Enterprise Management Co LLC
66.58M
EVTL logo
EVTL
Vertical Aerospace Ltd
346.79M
FFAI logo
FFAI
Faraday Future Intelligent Electric Inc
71.97M
RYDE logo
RYDE
Ryde Group Ltd
58.70M
news about stocks that are below 10 dollar
Intellectia · 100 candidates
Region: USPrice: $1.00 - $10.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000News Driver: Positive, Negative
Ticker
Name
Market Cap$
top bottom
XWEL logo
XWEL
XWELL Inc
6.98M
LRMR logo
LRMR
Larimar Therapeutics Inc
494.39M
VSME logo
VSME
VS Media Holdings Ltd
5.06M
EVH logo
EVH
Evolent Health Inc
350.52M
NVTS logo
NVTS
Navitas Semiconductor Corp
2.27B
SBET logo
SBET
Sharplink Inc
1.46B
what about health tech stocks and robots?
Intellectia · 18 candidates
Market Cap: 50.00M - 50.00BWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
47.26B
SYM logo
SYM
Symbotic Inc
36.98B
TER logo
TER
Teradyne Inc
36.32B
VEEV logo
VEEV
Veeva Systems Inc
36.12B
ZBRA logo
ZBRA
Zebra Technologies Corp
12.31B
DOCS logo
DOCS
Doximity Inc
7.50B
show me good penny stocks
Intellectia · 41 candidates
Market Cap: <= 1000.00MPrice: <= $5.00Beta: HighRiskWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
IOVA logo
IOVA
Iovance Biotherapeutics Inc
996.39M
MVST logo
MVST
Microvast Holdings Inc
951.73M
EVGO logo
EVGO
EVgo Inc
951.67M
REAX logo
REAX
Real Brokerage Inc
781.54M
URG logo
URG
Ur-Energy Inc
726.09M
BTBT logo
BTBT
Bit Digital Inc
721.79M
please I only need just one penny stock 🙏
Intellectia · 125 candidates
Market Cap: <= 500.00MPrice: <= $5.00Beta: HighRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True
Ticker
Name
Market Cap$
top bottom
CAN logo
CAN
Canaan Inc
498.64M
ORGO logo
ORGO
Organogenesis Holdings Inc
487.34M
GEVO logo
GEVO
Gevo Inc
487.04M
CLNE logo
CLNE
Clean Energy Fuels Corp
486.85M
CERS logo
CERS
Cerus Corp
485.98M
ALT logo
ALT
Altimmune Inc
482.06M

Whales Holding EVH

C
Castle Hook Partners LP
Holding
EVH
-2.23%
3M Return
R
Rock Springs Capital Management LP
Holding
EVH
-5.31%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Evolent Health Inc (EVH) stock price today?

The current price of EVH is 2.28 USD — it has increased 5.07

What is Evolent Health Inc (EVH)'s business?

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

What is the price predicton of EVH Stock?

Wall Street analysts forecast EVH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVH is9.33 USD with a low forecast of 5.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evolent Health Inc (EVH)'s revenue for the last quarter?

Evolent Health Inc revenue for the last quarter amounts to 468.72M USD, decreased -27.50

What is Evolent Health Inc (EVH)'s earnings per share (EPS) for the last quarter?

Evolent Health Inc. EPS for the last quarter amounts to -3.85 USD, increased 1325.93

How many employees does Evolent Health Inc (EVH). have?

Evolent Health Inc (EVH) has 4200 emplpoyees as of April 01 2026.

What is Evolent Health Inc (EVH) market cap?

Today EVH has the market capitalization of 254.54M USD.